View : 623 Download: 0
Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation
- Title
- Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation
- Authors
- Yang D.-H.; Lee J.-J.; Mun Y.-C.; Shin H.-J.; Kim Y.-K.; Cho S.-H.; Chung I.-J.; Seong C.-M.; Kim H.-J.
- Ewha Authors
- 성주명; 문영철
- SCOPUS Author ID
- 성주명
; 문영철![scopus](/images/layout/icon2.png)
- Issue Date
- 2007
- Journal Title
- American Journal of Hematology
- ISSN
- 0361-8609
- Citation
- American Journal of Hematology vol. 82, no. 1, pp. 1 - 5
- Indexed
- SCI; SCIE; SCOPUS
![scopus](/images/layout/scopus2.gif)
- Document Type
- Article
- Abstract
- CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease-free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56- group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56- group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the C056+ patients was significantly shorter than the CD56- patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. © 2006 Wiley-Liss, Inc.
- DOI
- 10.1002/ajh.20739
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML